5.35
+0.07(+1.33%)
Currency In USD
| Previous Close | 5.28 |
| Open | 5.25 |
| Day High | 5.42 |
| Day Low | 5.02 |
| 52-Week High | 31.01 |
| 52-Week Low | 4.55 |
| Volume | 242,330 |
| Average Volume | 566,151 |
| Market Cap | 80.37M |
| PE | -1.09 |
| EPS | -4.89 |
| Moving Average 50 Days | 8.3 |
| Moving Average 200 Days | 17.76 |
| Change | 0.07 |
If you invested $1000 in Jasper Therapeutics, Inc. (JSPR) since IPO date, it would be worth $54.48 as of March 11, 2025 at a share price of $5.35. Whereas If you bought $1000 worth of Jasper Therapeutics, Inc. (JSPR) shares 3 years ago, it would be worth $157.82 as of March 11, 2025 at a share price of $5.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
GlobeNewswire Inc.
Mar 01, 2025 5:45 PM GMT
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting
GlobeNewswire Inc.
Feb 28, 2025 1:00 PM GMT
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell d
Jasper Therapeutics to Present at Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 25, 2025 9:30 PM GMT
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mas